Age-related mutations and chronic myelomonocytic leukemia

Leukemia

Volumn 30, Issue 4, 2016, Pages 906-913

  Mason, C C ^a,b   Khorashad, J S ^a   Tantravahi, S K ^a   Kelley, T W ^b   Zabriskie, M S ^a   Yan, D ^a   Pomicter, A D ^a   Reynolds, K R ^a   Eiring, A M ^a   Kronenberg, Z ^b   Sherman, R L ^c   Tyner, J W ^d   Dalley, B K ^a   Dao, K H ^d   Yandell, M ^b   Druker, B J ^d   Gotlib, J ^e   O'Hare, T ^a,b   Deininger, M W ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c North American Association of Central Cancer Registries   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARIH1 GENE; ARTICLE; ASXL1 GENE; CANCER SURVIVAL; CBL GENE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; CSMD1 GENE; DNAH2 GENE; EZH2 GENE; FAT4 GENE; GENE MUTATION; GENE SEQUENCE; HEMATOPOIESIS; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; RUNX1 GENE; SETBP1 GENE; SOMATIC MUTATION; SRSF2 GENE; TET2 GENE; ADULT; AGED; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; EXOME; FEMALE; FOLLOW UP; GENETICS; HIGH THROUGHPUT SEQUENCING; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ARCHEASE PROTEIN, HUMAN; PROTEIN; TUMOR MARKER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; EXOME; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIESIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEINS; SURVIVAL RATE; YOUNG ADULT;

EID: 84955618325     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.337     Document Type: Article

References (44)

1. Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013; 27: 1504-1510
2. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 87: 743-745
3. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82: 358-367
4. Tyner JW, Loriaux MM, Erickson H, Eide CA, Deininger J, MacPartlin M, et al. High-Throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. Leukemia 2009; 23: 406-409
5. Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010; 151: 365-375
6. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-Abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116: 3923-3932
7. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011; 118: 3932-3941
8. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; 31: 2428-2436
9. Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 2014; 28: 2206-2212
10. Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080-3088
11. Laborde RR, Patnaik MM, Lasho TL, Finke CM, Hanson CA, Knudson RA, et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia 2013; 27: 2100-2102
12. Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross NC, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in480% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 2011; 25: 877-879
13. Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-Terminal region might predict acute myeloid leukemia transformation. Leukemia 2009; 23: 1426-1431
14. Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009; 94: 1676-1681
15. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010; 28: 3858-3865
16. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472-1478
17. McKerrell T, Park N, Moreno T, Grove CS, Ponstingl H, Stephens J, et al. Leukemiaassociated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep 2015; 10: 1239-1245
18. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-2487
19. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-2498
20. Pang WW, Price EA, Sahoo D, Beerman I, Maloney WJ, Rossi DJ, et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA 2011; 108: 20012-20017
21. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008; 111: 1534-1542
22. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-333
23. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing nextgeneration DNA sequencing data. Genome Res 2010; 20: 1297-1303
24. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-576
25. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079
26. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-Throughput sequencing data. Nucleic Acids Res 2010; 38: e164
27. Yandell M, Huff C, Hu H, Singleton M, Moore B, Xing J, et al. A probabilistic diseasegene finder for personal genomes. Genome Res 2011; 21: 1529-1542
28. Kohane IS, Hsing M, Kong SW. Taxonomizing, sizing, and overcoming the incidentalome. Genet Med 2012; 14: 399-404
29. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004; 91: 355-358
30. Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-Adjusted cancer rates. Stat Methods Med Res 2006; 15: 547-569
31. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840-849
32. Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004; 45: 1311-1318
33. Allen LJS. An Introduction to Stochastic Processes with Applications to Biology. Pearson Education, Inc: Upper Saddle River, NJ, 2003
34. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012; 22: 180-193
35. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726
36. Inoue D, Kitaura J, Matsui H, Hou HA, Chou WC, Nagamachi A, et al. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS. Leukemia 2015; 29: 847-857
37. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of Secondary Acute Myeloid Leukemia. N Engl J Med 2012; 366: 1090-1098
38. Durinck S, Ho C, Wanj NJ, Liao W, Jakkula LR, Collisson EA, et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov 2011; 1: 137-143
39. Youn A, Simon R. Estimating the order of mutations during tumorigenesis from tumor genome sequencing data. Bioinformatics 2012; 28: 1555-1561
40. Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell 2010; 6: 265-278
41. Cho RH, Sieburg HB, Muller-Sieburg CE. A new mechanism for the aging of hematopoietic stem cells: aging changes the clonal composition of the stem cell compartment but not individual stem cells. Blood 2008; 111: 5553-5561
42. Beerman I, Bhattacharya D, Zandi S, Sigvardsson M, Weissman IL, Bryder D, et al. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci USA 2010; 107: 5465-5470
43. Chambers SM, Shaw CA, Gatza C, Fisk CJ, Donehower LA, Goodell MA. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biol 2007; 5: e201
44. King KY, Goodell MA. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat Rev Immunol 2011; 11: 685-692